N4 Pharma PLC Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Nigel Theobald, was filed 10 Apr 2019.
N4 Pharma PLC: what insiders have been doing
Every trade that managers of N4 Pharma PLC disclose to RNS (LSE) is tracked on this page. The past year has been quiet: not a single insider filing for N4 Pharma PLC. The previous disclosure was published on 10 April 2019.
Since 2017, the database holds 3 purchases and no sales by insiders of the company.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Since the insiders bought
- +33.3%Entry £0.04 · Close at T+365 £0.06
- +33.3%Entry £0.04 · Close at T+365 £0.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 67,343 shares@ £0.0444100.0% of flowLondon Stock Exchange, XLONISIN GB00BYW8QM32FCA-NSM:LSE20190410115211_14036236_20200326185043788_16879-0Canonical exit: 9 Jul 2019 (T+90)
- 67,343 shares@ £0.0444100.0% of flowLondon Stock Exchange, XLONISIN GB00BYW8QM32FCA-NSM:LSE20190410115211_14036236_20200326185043788_16879-1Canonical exit: 9 Jul 2019 (T+90)
- 56,656 shares@ £0.079359.3% of flowLondon Stock Exchange, AIMISIN GB00BYW8QM32FCA-NSM:LSE20171110160442_13428215_20200330131534375_9370Canonical exit: 8 Feb 2018 (T+90)
3 of 3 declarations
About N4 Pharma PLC
N4 Pharma PLC is a company focused on developing new drug formulations. It aims to enhance the effectiveness of existing treatments.
